A 55-year-old woman has a biopsy-proven invasive lobular carcinoma, 3 cm in size, ER+/PR+, HER2-negative, with an Oncotype DX recurrence score of 18. She has no axillary node involvement. According to the TAILORx trial data, what is the recommended adjuvant systemic therapy?
- A Chemotherapy plus endocrine therapy
- B Endocrine therapy alone ✓
- C Chemotherapy alone for 6 months
- D Trastuzumab plus endocrine therapy
Correct answer: B. Endocrine therapy alone
Explanation
TAILORx demonstrated that postmenopausal women with node-negative, HR+/HER2- early breast cancer and an Oncotype DX recurrence score of 0–25 derive no benefit from adding chemotherapy to endocrine therapy; endocrine therapy alone is sufficient. A score of 18 falls within the low-intermediate range where chemotherapy is not beneficial in postmenopausal patients.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.